Microbot Medical Inc stock (US5950101098): First North Carolina LIBERTY system deal highlights U.S. roll-out

Microbot Medical has signed its first North Carolina healthcare system for the LIBERTY endovascular robotic system, extending the U.S. commercialization footprint for the Nasdaq-listed stock as investors track early adoption milestones.

Microbot Medical has reported a new commercial milestone in the United States, securing its first North Carolina-based healthcare system to adopt the LIBERTY endovascular robotic system, according to a company news release published on 06/02/2026 from Hingham, Massachusetts.GlobeNewswire as of 06/02/2026 The Nasdaq-listed stock trades in the United States under the ticker MBOT, aligning the latest contract win with the company’s broader home-market strategy.

The newly announced customer is described as a leading academic healthcare system operating a multi-hospital network across North Carolina, and it is the first LIBERTY user in the Southeast and Mid-Atlantic region, complementing prior placements in the Northeast United States.Microbot Medical investor relations as of 06/02/2026 Management framed the agreement as further evidence of expanding geographic penetration in its domestic market as the company progresses from development to commercial deployment of its robotic platform.

The stock traded around USD 1.98 on Nasdaq on 06/02/2026, corresponding to a market capitalization of roughly USD 133 million, after delivering a gain of more than 9 percent over the prior week as market participants responded to the latest adoption news.Investing.com as of 06/02/2026 For investors in Germany, the shares also trade on secondary venues such as Tradegate in euros, providing an additional access point to the U.S.-based medtech name.

The North Carolina healthcare system joins a growing list of U.S. hospitals and networks that have signed on to use the LIBERTY endovascular robotic system, which Microbot positions as a remotely operated, disposable robotic platform designed to assist physicians in minimally invasive vascular procedures.Barchart as of 06/02/2026 Company statements emphasize the potential for radiation exposure reduction and procedure-room efficiency gains, themes that have drawn attention in the U.S. medical-technology sector.

The announcement comes as the U.S. healthcare system continues to focus on workflow optimization in interventional radiology and cardiology labs, with hospitals seeking technologies that can be integrated into existing infrastructure while offering remote operation capabilities. Microbot’s progress in signing multi-hospital networks is being watched as an early indicator of the LIBERTY system’s commercial traction in the United States.

As of: 06/02/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Microbot Medical Inc
• Sector/industry: Medical technology / robotic-assisted surgery
• Headquarters/country: Hingham, United States
• Core markets: United States with an initial focus on leading academic and regional hospital systems
• Key revenue drivers: LIBERTY endovascular robotic system sales, associated disposables, and potential service agreements
• Home exchange/listing venue: Nasdaq Capital Market (MBOT)
• Trading currency: USD

Microbot Medical Inc: core business model

Microbot Medical focuses on commercializing its LIBERTY robotic platform for endovascular procedures, aiming to generate revenue primarily from system placements and recurring single-use component sales to hospitals and healthcare networks.

Latest quarterly results for Microbot Medical Inc at a glance

While the latest North Carolina contract highlights the company’s commercial roll-out, Microbot’s financial statements still reflect a transition-stage medtech profile with limited product revenue and ongoing research, development, and commercialization expenses. In its most recent reported quarter, the company continued to incur operating losses as it invested in regulatory, clinical, and go-to-market activities related to LIBERTY, underscoring that near-term performance is shaped more by cash burn and funding access than by mature earnings metrics.Microbot Medical investor relations as of 05/2026

Investors following the stock typically monitor quarterly updates from the company’s U.S. filings for progress on commercialization milestones, cash runway, and any changes in operating expense levels, rather than traditional benchmarks such as price-earnings ratios or dividend yields. The timing and scale of additional LIBERTY placements, particularly with multi-site hospital systems in the United States, will likely play a central role in how upcoming results are interpreted.

Conclusion

The first North Carolina healthcare system contract adds another data point to Microbot Medical’s U.S. commercialization story, showing that LIBERTY is moving beyond initial early-adopter sites into broader regional networks. Against the backdrop of loss-making but investment-heavy quarterly results, the pace at which additional hospitals commit to the robotic platform is likely to remain a central focus for market observers tracking the stock’s development.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.